SpaceOAR® Hydrogel News
Augmenix, Inc. Announces SpaceOAR® Hydrogel is Now Available to Millions More Americans
Augmenix, Inc. is pleased to announce that the company’s leading product, SpaceOAR hydrogel, is now available to millions of American men covered under Medicare, Medicaid, and Aetna, Inc.
Beaumont Hospital Using SpaceOAR® Hydrogel To Reduce Side Effects of Prostate Cancer Treatment
The hydrogel is placed by Dr. Daniel Krauss, MD., a radiation oncologist with a primary focus on prostate and bladder cancers. He places the gel under local or general anesthesia in an outpatient setting. He is a leading expert in prostate cancer treatment with brachytherapy, a high-dose, internal radiation treatment.
UsToo and Dr. Daniel Fried Present Live Webcast and Q and A on Prostate Cancer Radiation Therapy
The event featured a presentation from renowned radiation oncologist Daniel B. Fried, MD, MPH, PhD, who practices at the Gibbs Cancer Center and Research Institute in Greenville, S.C discussing radiation therapy as an option for prostate cancer treatment.
Augmenix, Inc. Announces Aetna’s Positive Coverage Decision for the SpaceOAR® Hydrogel
The Relaunch of SpaceOAR Hydrogel Clinical Publications!
Now it’s easier than ever to find the peer-reviewed papers, abstracts and posters that evaluate the efficacy of SpaceOAR hydrogel.
Augmenix® Announces Medicare Reimbursement Rates for 2018
Augmenix® Announces Medicare Reimbursement Rates for the new CPT Code 55874, which will be used to bill SpaceOAR® Hydrogel, Effective January 2018